EU Ruling Turns Days Into €millions For Companies
This article was originally published in Scrip
Executive Summary
Just a few days could make a big difference for your company, perhaps millions of Euros. Thanks to a ruling from the Court of Justice of the European Union, some innovative products could have their market exclusivity period extended in some EU markets by a number of days or maybe weeks. This may not seem much on the surface, but it could mean a windfall for the originator company and isn't all bad news for the generics companies, explains Mike Gilbert, a partner at Marks & Clerk Solicitors.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.